Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis

Clinical trial NCT06867991 · RECRUITING

Trial details

NCT number: NCT06867991
Sponsor: The First People's Hospital of Changzhou
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Start date: 2024-11-08
Primary completion: 2026-11-08
Enrollment: 200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.